Impact of anti-tumour necrosis factor α treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis

Annals of the Rheumatic Diseases

Volumn 63, Issue 12, 2004, Pages 1670-1672

  Listing, J ^a   Brandt, J ^b   Rudwaleit, M ^b   Zink, A ^a   Sieper, J ^b   Braun, J ^c  

^a DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c RHEUMAZENTRUM RUHRGEBIET   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABSENTEEISM; ADULT; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; COST OF ILLNESS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GERMANY; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; SICK LEAVE; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 9644289480     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.017327     Document Type: Article

References (11)

1. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis 2002;61 (suppl III):iii8-18.
2. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis-results from the German rheumatological database. J Rheumatol 2000;27:613-22.
3. Boonen A, Chorus A, Miedema H, van der Heijde D, van der Tempel H, van der Linden S. Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 2001;60:353-8.
4. Boonen A, van der Heijde D, Landewe R, Spoorenberg A, Schouten H, Rutten-Van Molken M, et al. Work status and productivity costs due to ankylosing spondylitis comparison of three European countries. Ann Rheum Dis 2002;61:429-37.
5. Ward MM. Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 1999;12:247-55.
6. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
7. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis. An open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003;48:2224-33.
8. Brondt J, Listing J, Alten R, Burmester R, Gromnica-Ihle E, Kellner H, et al. Two year follow up results of a controlled trial of the anti-TNFα antibody infliximab in active ankylosing spondylitis. Arthritis Rheum 2003;48(suppl):S172-3.
9. Minden K, Niewel M, Listing J, Biedermann T, Schöntube M, Zink A. Burden and cost of illness in patients with juvenile idiopathic arthritis. Ann Rheum Dis 2003;63:836-42.
10. Anonymous. Deutsche Krankenhausgesellschaft: Eckdaten der Krankenhaus-kostenstatistik 2001/2000. (German Society of Medical Hospitals: Statistic of the costs of hospital stays,).http://www.dkgev.de/pub/newpdf/pdf- 2003/ RS93-03_Anlage1-Krankenhausstatistik2001.doc.pdf.
11. Listing J, Schlittgen R. A nonparametric test for random dropouts. Biom J 2003;45:113-27.